RELIEF Therapeutics Holding AG Logo

RELIEF Therapeutics Holding AG

Developing and commercializing novel therapies for rare and ultra-rare diseases.

RLF | SW

Overview

Corporate Details

ISIN(s):
CH1251125998
LEI:
506700IT19260EVD7916
Country:
Switzerland
Address:
avenue de Sécheron 15, 1202 Genève
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

RELIEF Therapeutics Holding AG is a commercial-stage biopharmaceutical company focused on developing and commercializing novel, patent-protected therapies for rare and ultra-rare diseases with high unmet medical needs. The company's mission is to advance its pipeline of therapeutic candidates to provide patients with treatments that can significantly improve their condition and quality of life. Its strategy involves advancing clinical programs, such as its candidate for Epidermolysis Bullosa (RLF-TD011), and pursuing strategic transactions, including partnerships and business combinations, to accelerate development and market access for its products.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-25 07:00
Relief Therapeutics and NeuroX Unveil Joint Presentation and Financial Outlook …
English 11.1 KB
2025-11-25 01:00
Relief Therapeutics and NeuroX Unveil Joint Presentation and Financial Outlook …
English 8.4 KB
2025-11-14 18:20
Relief Therapeutics Shareholders Approve Business Combination with NeuroX
English 12.9 KB
2025-11-14 01:00
Relief Therapeutics Shareholders Approve Business Combination with NeuroX
English 10.3 KB
2025-10-29 07:00
Relief Therapeutics Announces Positive Results from Pivotal Bioequivalence Stud…
English 12.2 KB
2025-10-29 01:00
Relief Therapeutics Announces Positive Results from Pivotal Bioequivalence Stud…
English 10.0 KB
2025-10-24 06:59
Relief Therapeutics Convenes Extraordinary General Meeting
English 12.0 KB
2025-10-24 02:00
Relief Therapeutics Convenes Extraordinary General Meeting
English 9.5 KB
2025-10-08 07:00
Relief Therapeutics and NeuroX, Successor to MindMaze, Sign Definitive Agreemen…
English 19.8 KB
2025-10-08 02:00
Relief Therapeutics and NeuroX, Successor to MindMaze, Sign Definitive Agreemen…
English 17.3 KB
2025-08-14 07:00
Relief Therapeutics Publishes 2025 Half-Year Report
English 9.0 KB
2025-08-14 02:00
Relief Therapeutics Publishes 2025 Half-Year Report
English 6.8 KB
2025-08-11 07:00
Relief Therapeutics Advances Publication of 2025 Half-Year Report
English 6.9 KB
2025-08-11 02:00
Relief Therapeutics Advances Publication of 2025 Half-Year Report
English 4.8 KB
2025-07-29 07:00
Relief Therapeutics Announces Proposed Business Combination with NeuroX, succes…
English 15.9 KB

Automate Your Workflow. Get a real-time feed of all RELIEF Therapeutics Holding AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for RELIEF Therapeutics Holding AG

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for RELIEF Therapeutics Holding AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

AVACTA GROUP PLC Logo
Developing targeted cancer therapies with a platform that delivers drugs directly to tumors.
United Kingdom
AVCT
AVADEL PHARMACEUTICALS PLC Logo
Develops once-at-bedtime therapies for adults with narcolepsy using innovative drug delivery.
United States of America
AVDL
Avalon GloboCare Corp. Logo
Delivers clinical lab services & develops diagnostics, CAR-T therapies, and exosome technology.
United States of America
ALBT
Avidity Biosciences, Inc. Logo
Pioneering targeted RNA therapies that treat the root cause of rare muscle diseases.
United States of America
RNA
Axogen, Inc. Logo
Develops surgical solutions, including nerve allografts, for peripheral nerve repair and regeneration.
United States of America
AXGN
Axsome Therapeutics, Inc. Logo
Biopharma company developing novel therapies for central nervous system (CNS) conditions.
United States of America
AXSM
AYTU BIOPHARMA, INC Logo
Specialty pharma advancing innovative medicines for CNS diseases like MDD and ADHD.
United States of America
AYTU
Azitra, Inc. Logo
Developing engineered proteins and live biotherapeutics for rare skin diseases.
United States of America
AZTR
Bachem Holding AG Logo
A CDMO developing and manufacturing peptides and oligonucleotides for pharma and biotech.
Switzerland
BANB
Barinthus Biotherapeutics plc. Logo
Develops T cell immunotherapies for autoimmune and chronic infectious diseases.
United States of America
BRNS

Talk to a Data Expert

Have a question? We'll get back to you promptly.